Targeting CLEC4E in immunosuppressive tumour-associated macrophages via BET inhibition.

ABSTRACT:

Background

Immunosuppressive tumour-associated macrophages (TAMs) represent a promising target for cancer immunotherapy; however, existing TAM-directed therapies have shown limited clinical efficacy. C-type lectin domain family 4 member E (CLEC4E), a pro-inflammatory molecule expressed on macrophages, was recently found to be highly enriched in TAMs. This study aims to elucidate the role of CLEC4E in TAMs and identify potential therapeutic agents targeting CLEC4E, and to clarify the mechanism of Bromodomain and extraterminal domain (BET) inhibitor NHWD-870 in downregulating CLEC4E.

Methods

We first assessed the correlation between CLEC4E expression and survival in melanoma patients. Clec4e^flox/flox Lyz2-cre (knockout) and Clec4e^flox/flox (control) mice

SUBMITTER: Liao M 

PROVIDER: S-EPMC12521789 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature